News

Orkambi (ivacaftor/lumacaftor) can significantly reduce the number of days people with cystic fibrosis (CF) require intravenous antibiotics for flares and helps with weight gain — independently of a patient’s level of lung function at the start of treatment, a real-world study reported. While the greatest lung improvements were…

The common mutations that cause Pseudomonas aeruginosa to lose their ability to move are associated with a higher production of two complex sugar molecules implicated in the formation of biofilms — slimy layers of microorganisms that stick to wet surfaces and protect them from antibiotics and the host’s…

Cystic fibrosis (CF) patients who monitored their lung function at home using NuvoAir‘s handheld spirometer and smartphone app were able to better engage in telemedicine, a U.K. survey found, with these patients reporting a more than 30% drop in their number of scheduled and urgent in-person consultations. The study based…

NHS England and Vertex Pharmaceuticals have reached an agreement that will allow access to Vertex’s Kaftrio (ivacaftor/tezacaftor/elexacaftor), a triple combination therapy for cystic fibrosis (CF) to be used in a combination regimen with Kalydeco, as soon as the medication is approved by the European…

Anxiety related to fears of COVID-19 infection was higher among mothers of children with cystic fibrosis (CF) than those of healthy children, although teenage patients themselves were less anxious than age-matched peers without CF, a survey of families in Turkey reported. Mothers of young patients with chronic lung infections, and…

The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor) as a treatment for cystic fibrosis (CF) in people 12 and older who have either two F508del mutations or one F508del mutation and…

Nontuberculous mycobacteria (NTM), a type of infectious bacteria, is able to survive being dried for a full day, a study found, suggesting that drying is not a sufficient way to disinfect nebulizers used by people with cystic fibrosis (CF). The study, “Susceptibility of the Mycobacterium…

A potential way of killing persistent bacterial infections like those common to people with cystic fibrosis (CF) — using nutrient channels that may exist within bacterial communities to carry antibiotics — is suggested by a research team at the University of Strathclyde in Glasgow. Their study, “…

AR-501, an inhaled treatment candidate for chronic lung infections in people with cystic fibrosis (CF), has been deemed safe and well-tolerated in healthy volunteers, results from the first part of a Phase 1/2a clinical trial show. The trial’s safety monitoring committee (SMC) and a data safety monitoring board…

Renovion has raised $8.1 million in a financing round, supporting further development and planned clinical testing of ARINA-1, a nebulized treatment for chronic lung diseases like cystic fibrosis (CF) and non-CF bronchiectasis, and for lung transplants. “Patient and laboratory studies have…